Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Upgrades and Price Target Increases for Descartes Systems Group

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Biotechnology Stock Market Today (1)
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Analyst Justin Long of Stephens & Co. has reaffirmed an Overweight rating on Descartes Systems Group (NASDAQ:DSGX) and increased the price target to $107, up from $105. This move follows previous adjustments by Stephens & Co., which also maintained an Overweight rating on the company and raised the price target from $93 to $105. Furthermore, StockNews.com recently upgraded Descartes Systems Group, raising the price target from $94 to $105 and changing the rating from “hold” to “buy”.

March 7, 2024

DSGX Stock Price Analysis: Strong Momentum Followed by After-Hours Drop on March 7, 2024

On March 7, 2024, DSGX stock showed strong price momentum as it traded near the top of its 52-week range and above its 200-day simple moving average. The price of DSGX shares increased by $2.42 since the market last closed, representing a 2.85% rise. However, despite the initial increase, the stock dropped by $4.22 in after-hours trading, closing at $87.32. The after-hours drop could be attributed to various factors, such as profit-taking by investors who wanted to lock in their gains from the day’s trading session or new information released after the market closed. Investors should continue to monitor the stock’s performance and stay informed about any news or events that may impact its price movements in the future.

DSGX Stock Analysis: Steady Performance with Consistent Revenue and Net Income Growth

On March 7, 2024, DSGX stock demonstrated a steady performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $572.93 million, showing a 17.88% increase compared to the previous year. However, the total revenue remained flat at $144.70 million in the last quarter.

Similarly, DSGX’s net income for the past year was $115.91 million, reflecting a 13.37% increase from the previous year. The net income also remained unchanged at $26.60 million in the last quarter. Earnings per share (EPS) for the past year stood at $1.34, showing a 13.31% increase from the previous year. The EPS also held flat at $0.31 in the last quarter.

Overall, DSGX stock showed a consistent performance on March 7, 2024, with a stable revenue, net income, and EPS. Investors may view DSGX as a reliable investment option given its steady financial growth over the past year. However, it is essential to conduct further research and analysis before making any investment decisions.

Tags: DSGX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Credit

Conflicting Analyst Opinions on Aris Water Solutions Price Target

SO stock news

Analyst Edward Kelly Maintains Underweight Rating on United Natural Foods Lowers Price Target

Biotechnology Market Capitalization

Analyst Upgrades Price Target for Nuvation Bio to 5

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com